Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $92.44 Average Target Price from Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have received an average recommendation of "Buy" from the twelve research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, nine have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $92.44.

A number of equities analysts have weighed in on JANX shares. HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. Scotiabank dropped their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a report on Friday, February 28th. Wedbush reiterated an "outperform" rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Cantor Fitzgerald restated an "overweight" rating and issued a $200.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Finally, William Blair reiterated an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th.

Insiders Place Their Bets

In related news, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $32.15, for a total value of $107,188.10. Following the completion of the transaction, the insider now owns 82,139 shares of the company's stock, valued at approximately $2,640,768.85. This trade represents a 3.90 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. purchased 341,742 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was bought at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the transaction, the director now owns 9,658,988 shares of the company's stock, valued at $295,951,392.32. This represents a 3.67 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 11,668 shares of company stock valued at $548,183 in the last quarter. 29.40% of the stock is currently owned by insiders.

Remove Ads

Institutional Investors Weigh In On Janux Therapeutics

Institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. raised its holdings in Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after buying an additional 442 shares during the period. Rhumbline Advisers increased its position in Janux Therapeutics by 1.6% during the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock valued at $2,043,000 after acquiring an additional 599 shares during the last quarter. Kennedy Capital Management LLC increased its position in Janux Therapeutics by 7.9% during the fourth quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company's stock valued at $681,000 after acquiring an additional 928 shares during the last quarter. MetLife Investment Management LLC raised its stake in shares of Janux Therapeutics by 5.8% in the fourth quarter. MetLife Investment Management LLC now owns 17,298 shares of the company's stock valued at $926,000 after acquiring an additional 949 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Janux Therapeutics by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock worth $596,000 after acquiring an additional 1,095 shares during the last quarter. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Trading Down 4.5 %

Janux Therapeutics stock traded down $1.26 during trading on Monday, reaching $26.99. The company had a trading volume of 834,377 shares, compared to its average volume of 848,176. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -23.07 and a beta of 3.23. The firm's 50-day simple moving average is $34.46 and its 200 day simple moving average is $45.46. Janux Therapeutics has a 52 week low of $25.77 and a 52 week high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, analysts predict that Janux Therapeutics will post -1.38 earnings per share for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.